EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Neurofilament Light Chain Concentration in the Prediction of Treatment Response in Multiple Sclerosis

Nahid Moradi iD, Sifat Sharmin, Charles B Malpas, Jens Kuhle, Pascal Benkert, David Leppert, Eva Kubala Havrdová, Dana Horáková, Pavlína Kleinová, Tomas Uher iD, Ali Manouchehrinia, Jan Hillert und 7 weitere

European Journal of Neurology · 2026

DOI: 10.1111/ene.70505 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, 2026. Verfasst von Nahid Moradi und 18 weiteren Autor:innen. Beteiligte Einrichtung: Core, Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Neurofilament Proteins, Multiple Sclerosis, Immunologic Factors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Management of multiple sclerosis (MS) revolves around timely initiation of effective disease‐modifying therapy. Here we investigate the additive predictive value of age‐adjusted normalised neurofilament light chain (NfL) concentrations when combined with a clinicodemographic model of treatment response.

Methods

Data were obtained from three sources: the University Hospital Basel, the SET cohort in Prague, and EIMS and IMSE cohorts from Sweden. NfL samples were collected within 90 days of baseline, age‐adjusted and normalised using a reference population. Principal component analysis reduced the dimensionality of clinicodemographic predictors. Cox proportional hazards models estimated cumulative hazards of relapse, 6‐month confirmed disability worsening and 9‐month confirmed disability improvement, with and without NfL. Uno's concordance index compared prediction accuracy across pooled and treatment‐specific models.

Results

The study included 1716 individuals across three therapies: interferon β ( n = 554), fingolimod ( n = 307) and natalizumab ( n = 369). Clinicodemographic characteristics were associated with relapse and disability outcomes. While NfL showed no association in the pooled cohort, in the natalizumab group, higher NfL predicted lower probability of disability improvement (HR = 0.819, 95% CI: 0.814–0.823). Pooled models predicted outcomes with moderate accuracy (relapse: 63.4%, disability worsening: 56.4%, improvement: 67.7%), with minimal contribution from NfL. In treatment‐specific models, NfL‐inclusive accuracy ranged from 51.3%–62.2% (relapse), 54.3%–60.3% (worsening) and 65%–67.9% (improvement), closely matching models without NfL.

Conclusion

In well‐characterised MS patients treated with interferon β, fingolimod or natalizumab, clinicodemographic information provides modest prognostic value; however, NfL adds minimal incremental utility.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neurofilament ProteinsMultiple SclerosisImmunologic FactorsHumansFemaleInterferon-betaMaleNatalizumabAdultFingolimod HydrochlorideTreatment OutcomeMiddle AgedCohort StudiesPredictive Value of TestsTreatment Effect Heterogeneity

Stichwörter der Autor:innen

multiple sclerosisneurofilament lightpredictionprincipal component analysistreatment response

Substanzen

neurofilament protein LNeurofilament ProteinsInterferon-betaNatalizumabFingolimod HydrochlorideImmunologic Factors

Autor:innen und Institutionen

  • Core, Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia.
  • Neuroimmunology Centre, Department of Neurology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
  • Melbourne School of Psychological Sciences, the University of Melbourne, Australia.
  • Neurologic Clinic and Policlinic, MS Centre and Research Centre for Clinical Neuroimmunology and Neuroscience Basel, University of Basel, Basel, Switzerland.
  • Clinical Trial Unit, Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland.
  • Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.

ORCID-Profile: Nahid Moradi, Tomas Uher, Ingrid Kochum

Förderung

  • National Health and Medical Research Council

Zitieren

APA

Moradi, N., Sharmin, S., Malpas, C. B., Kuhle, J., Benkert, P., Leppert, D., Havrdová, E. K., Horáková, D., Kleinová, P., Uher, T., Manouchehrinia, A., Hillert, J., Olsson, T., Kochum, I., Taylor, B. V., Barnett, M., Kilpatrick, T. J., Buzzard, K., & Kalincik, T. (2026). Neurofilament Light Chain Concentration in the Prediction of Treatment Response in Multiple Sclerosis. European Journal of Neurology. https://doi.org/10.1111/ene.70505

Vancouver

Moradi N, Sharmin S, Malpas CB, Kuhle J, Benkert P, Leppert D, et al. Neurofilament Light Chain Concentration in the Prediction of Treatment Response in Multiple Sclerosis. European Journal of Neurology. 2026. doi:10.1111/ene.70505

BibTeX
@article{Moradi2026,
  author = {Moradi, Nahid and Sharmin, Sifat and Malpas, Charles B and Kuhle, Jens and Benkert, Pascal and Leppert, David and Havrdová, Eva Kubala and Horáková, Dana and Kleinová, Pavlína and Uher, Tomas and Manouchehrinia, Ali and Hillert, Jan and Olsson, Tomas and Kochum, Ingrid and Taylor, Bruce V and Barnett, Michael and Kilpatrick, Trevor J and Buzzard, Katherine and Kalincik, Tomas},
  title = {Neurofilament Light Chain Concentration in the Prediction of Treatment Response in Multiple Sclerosis},
  journal = {European Journal of Neurology},
  year = {2026},
  doi = {10.1111/ene.70505}
}
Kostenlos starten →